Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - hypericum perforatum 30ch 1 % - pillules - 30ch - hypericum perforatum 30ch 1 %

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - amphotericin b - powder for solution for infusion - amphotericin b 50 mg - antimycotics for systemic use

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

american chemet corporation - copper present as cuprous oxide - wettable powder - copper present as cuprous oxide mineral-copper active 750.0 g/kg - fungicide - almond | apple | apricot | avocado | banana | bean | brassica vegetables | capsicum or pepper | carrot | celery | cherry | citru - angular leaf spot on cucurbit | anthracnose | ascochyta blight | bacterial black spot | bacterial blight | bacterial brown spot | bacterial canker | bacterial gummosis | bacterial leaf spot | bacterial soft rot | bacterial speck | bacterial spot | black rot | black spot | botrytis | brown rot - phytophthora citrophthora | brown spot on mandarin | cercospora leaf spot | chocolate spot on bean | citrus melanose | common blight | crown rot | downy mildew | early blight (target spot) | freckle | halo blight | late blight or irish blight | leaf curl | leaf spot | lemon scab | macadamia husk spot | peppery leaf spot | phytophthora stem canker | pink disease or limb blight | ring spot | rust | scab | septoria leaf spot - septoria spp. | septoria spot | shot hole | sooty blotch on apple, pear or citrus | walnut blight | alternaria leaf spot | bacterial blight | botrytis blight | botrytis cinerea | bunch rot-grey mould | corticium salmonicolor | corticum salmonicolor | grey mould | grey mould (nesting) | irish blight

New Zealand - English - Medsafe (Medicines Safety Authority)

weleda (new zealand) ltd - hypericum perforatum 33% (herba (flowering) succ. rec.) - oral solution - active: hypericum perforatum 33% (herba (flowering) succ. rec.) excipient: ethanol purified water

Ireland - English - HPRA (Health Products Regulatory Authority)

weleda (uk) limited - hypericum perforatum, calendula officinalis - ointment - %v/v

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: magnesium stearate; peg-40 hydrogenated castor oil; iron oxide yellow; hypromellose; purified water; microcrystalline cellulose; sodium starch glycollate type a; colloidal anhydrous silica; triethyl citrate; maize starch; purified talc; titanium dioxide; povidone; lactose monohydrate; polysorbate 80; methacrylic acid copolymer; sodium lauryl sulfate - relief of acute pain states in which there is an inflammatory component.,symptomatic treatment of primary dysmenorrhoea.

New Zealand - English - Ministry for Primary Industries

american chemet corporation - copper (i) oxide - copper (i) oxide 750 g/kg (as cu) - fungicide

United States - English - NLM (National Library of Medicine)

astellas pharma us, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b 50 mg in 12.5 ml - amb isome is indicated for the following: see dosage and administration for recommended doses by indication. amb isome is contraindicated in those patients who have demonstrated or have a known hypersensitivity to amphotericin b deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.

United States - English - NLM (National Library of Medicine)

leadiant biosciences, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe), dimyristoylphosphatidylcholine, dl- (unii: u86zgc74v5) (dimyristoylphosphatidylcholine, dl- - unii:u86zgc74v5), dimyristoylphosphatidylglycerol, dl- (unii: bi71wt9p3r) (dimyristoylphosphatidylglycerol, dl- - unii:bi71wt9p3r) - amphotericin b 5 mg in 1 ml - abelcet ® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin b therapy. this is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin b therapy (see description of clinical studies). description of clinical studies fungal infections data from 473 patients were pooled from three open-label studies in which abelcet ® was provided for the treatment of patients with invasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin b, or who had preexisting nephrotoxicity. results of these studies demonstrated effectiveness of abelcet ® in the treatment of invasive fungal infections as a second line therapy. patients were defined by their individual physician as being refractory to or failing conventional amphotericin b therapy based on overall clinical judgement after receiving a minimu

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amphotericin b (amphotericin) -